4//SEC Filing
MEYER ALAN R 4
Accession 0001596771-20-000114
CIK 0001228627other
Filed
Nov 8, 7:00 PM ET
Accepted
Nov 9, 6:47 PM ET
Size
9.9 KB
Accession
0001596771-20-000114
Insider Transaction Report
Form 4
MEYER ALAN R
Director
Transactions
- Award
Common Stock
2020-11-05+485,258→ 485,258 total - Award
Stock Option (right to buy)
2020-11-05+31,695→ 31,695 totalExercise: $1.21Exp: 2029-12-27→ Common Stock (31,695 underlying) - Award
Stock Option (right to buy)
2020-11-05+35,663→ 35,663 totalExercise: $0.90Exp: 2028-10-01→ Common Stock (35,663 underlying)
Footnotes (3)
- [F1]The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc.
- [F2]The option is fully vested.
- [F3]3,803 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2021, subject to continued service.
Documents
Issuer
Ocuphire Pharma, Inc.
CIK 0001228627
Entity typeother
Related Parties
1- filerCIK 0001212162
Filing Metadata
- Form type
- 4
- Filed
- Nov 8, 7:00 PM ET
- Accepted
- Nov 9, 6:47 PM ET
- Size
- 9.9 KB